NEOG NEOGEN CORP
Legal ·
A federal court dismissed the Michigan class action with prejudice on August 10, 2026 and plaintiffs have appealed. A Minnesota Securities Act class action and a Michigan derivative suit remain pending.
Neogen refinanced its term loan and revolving credit facility on April 4, 2025, with a new $450.0 million term loan and a $250.0 million revolver that matures April 4, 2030. The revolver had $100.0 million drawn at closing, and the company says the deal is leverage-neutral and cuts its rate, a claim the 8-K and the release do not test against the old terms.
Neogen filed a late-filing notice on January 10, 2025 for its quarterly report for the quarter ended November 30, 2024. The company expects a $461.4 million goodwill impairment on its Food Safety unit and a net loss of $456.3 million, against a loss of $3.5 million a year earlier.
Neogen develops, manufactures and markets products and services dedicated to food and animal safety. Its Food Safety segment sells mainly diagnostic test kits and complementary products such as culture media to food and animal feed producers and processors, to help prevent contamination and foodborne illness and to determine food quality and nutritional components. Its Animal Safety segment develops and markets veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent and insect control products and genomics testing services. Its drug detection products are sold worldwide to detect abused and therapeutic drugs in animals and animal products, and have expanded into workplace testing and human forensic markets. In July 2025 the company divested its global Cleaners and Disinfectants business. Neogen was formed as a Michigan corporation in June 1981. Its growth strategy includes increasing sales of existing products, introducing innovative products, growing international sales, and acquiring businesses and forming strategic alliances.
| Product or program | What it is | Stage |
|---|---|---|
| diagnostic test kits | Food safety test kits and complementary products such as culture media | |
| Animal Safety segment | Veterinary instruments, pharmaceuticals, vaccines and parasiticides for animals | |
| drug detection products | Detection of abused and therapeutic drugs in animals and animal products |
| Line | FY ended May 31, 2026 | FY ended May 31, 2025 |
|---|---|---|
| Revenue | $870.4 million | $894.7 million |
| Research and development | $18.4 million | $21.1 million |
| Net income (loss) | -$7.9 million | -$1.09 billion |
| Cash from operations | $83.2 million | $58.2 million |
| Cash and equivalents | $185.5 million | $129.0 million |
| Short-term investments | $0 |
Our latest story on this, dated Oct 7, 2026: "Neogen discloses appeal of dismissed Michigan securities suit and two related cases". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 10, 2025: "Neogen files NT 10-Q late-filing notice, expects $461.4 million goodwill impairment". The story links the filing or release it is based on. Read the story.
NEOGEN CORP trades under the ticker NEOG on NASDAQ.
NEOGEN CORP is listed on NASDAQ.
Our directory records NEOGEN CORP under United States.
aibio.space lists NEOGEN CORP among 2,820 public biotech companies and publishes its news here as stories appear.
Neogen develops, manufactures and markets products and services dedicated to food and animal safety. Its Food Safety segment sells mainly diagnostic test kits and complementary products such as culture media to food and animal feed producers and processors, to help prevent contamination and foodborne illness and to determine food quality and nutritional components.
diagnostic test kits: Food safety test kits and complementary products such as culture media
Animal Safety segment: Veterinary instruments, pharmaceuticals, vaccines and parasiticides for animals
$870.4 million for the fiscal year ended May 31, 2026, as reported to the SEC.
NEOGEN CORP reported a net loss of $7.9 million for the fiscal year ended May 31, 2026, and generated $83.2 million of cash from operations, per its annual report to the SEC.
$18.4 million in the fiscal year ended May 31, 2026, per its annual report.
$172.0 million in cash at Aug 31, 2026, per its 10-Q.
Our latest story on NEOGEN CORP, dated Oct 7, 2026: "Neogen discloses appeal of dismissed Michigan securities suit and two related cases". A federal court dismissed the Michigan class action with prejudice on August 10, 2026 and plaintiffs have appealed. A Minnesota Securities Act class action and a Michigan derivative suit remain pending. Source.
Our latest debt story, dated Apr 7, 2025: "Neogen refinances term loan and revolver with $450 million term loan, $250 million credit facility". Neogen refinanced its term loan and revolving credit facility on April 4, 2025, with a new $450.0 million term loan and a $250.0 million revolver that matures April 4, 2030. The revolver had $100.0 million drawn at closing, and the company says the deal is leverage-neutral and cuts its rate, a claim the 8-K and the release do not test against the old terms. Source.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio